Médecine

Paramédical

Autres domaines


S'abonner

Comorbidities in patients with palmoplantar plaque psoriasis - 15/02/21

Doi : 10.1016/j.jaad.2020.03.112 
Ran Greenberg, MD a, Tomer Goldsmith, MD a, David Zeltser, MD b, c, Itzhak Shapira, MD b, c, Shlomo Berliner, MD b, c, Ori Rogowski, MD b, c, Shani Shenhar-Tsarfaty, PhD b, c, Eli Sprecher, MD, PhD a, c, Hagit Matz, MD a, c,
a Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 
b Department of Internal Medicine C, D, and E, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 
c Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel 

Correspondence to: Hagit Matz, MD, Division of Dermatology, 6, Weizmann St, Tel Aviv 64239, Israel.Division of Dermatology6, Weizmann StTel Aviv64239Israel

Abstract

Background

Psoriasis has been shown to be associated with several comorbidities. Whether the palmoplantar subtype of plaque psoriasis carries similar risks for comorbidities as generalized plaque psoriasis remains to be defined.

Objective

To examine the association between palmoplantar plaque psoriasis and comorbidities known to be associated with generalized plaque psoriasis.

Methods

We retrospectively compared the prevalence of comorbidities previously found to be associated with generalized plaque psoriasis among 163 patients with palmoplantar plaque psoriasis who had been treated with topical psoralen and ultraviolet A from 2009 to 2017 and a cohort of 781 control individuals. Each patient with psoriasis was matched according to sex and age (±1 year) with up to 5 control individuals. Conditional logistic regression was used to evaluate the associations after matching.

Results

Diabetes mellitus (odds ratio [OR], 2.296), cardiovascular disease (OR, 1.797), and most remarkably, mood disorders (OR, 6.232) were significantly associated with palmoplantar plaque psoriasis. Dyslipidemia, hypertension, and psoriatic arthritis were more frequent among patients with palmoplantar plaque psoriasis, but those associations did not reach statistical significance.

Limitations

The retrospective nature of this study, the fact that some data were collected through a survey questionnaire, and the relatively small sample size suggest the need to validate the present data in a prospective manner. Additionally, within the psoriasis group, patients were assessed for the presence of comorbidities during the whole follow-up period, whereas the comorbidities of individuals in the control group were assessed during a baseline visit.

Conclusions

Several comorbidities known to be associated with psoriasis vulgaris were also found to be prevalent in a series of patients with plaque palmoplantar psoriasis. Individuals affected with plaque palmoplantar psoriasis showed a particularly high risk for mood disorders.

Le texte complet de cet article est disponible en PDF.

Key words : palmoplantar plaque psoriasis, psoriasis, psoriasis comorbidities, psoriatic arthritis, PUVA

Abbreviations used : CI, CVD, DM, HTN, IBD, MD, OR, PaPP, PsA, PUVA


Plan


 Funding sources: None.
 Conflicts of interest: None disclosed.
 IRB approval status: Reviewed and approved by the Tel Aviv Medical Center institutional review board (Helsinki Committee).
 Reprints not available from the authors.


© 2020  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 84 - N° 3

P. 639-643 - mars 2021 Retour au numéro
Article précédent Article précédent
  • Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis
  • Amy S. Paller, Linda Stein Gold, Jennifer Soung, Anna M. Tallman, David S. Rubenstein, Melinda Gooderham
| Article suivant Article suivant
  • Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation
  • Xuemei Gao, Xuhua Tang, Lu Ai, Qian Gao, Qiman Liao, Mukai Chen, Xiaohong Chen, Hui Zhou, Yanting Ye, Minyi Li, Jiande Han, Fang Wang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.